Please enable Javascript to use all features and improve your user experience.
EHC 2023
Programme
People
Search
DE
All people
Fabrizio Vernieri
Sort by Type
Date
Invited speaker
Invited lecture
Profiling non-responders and super-responders
Speaker
ePoster
P031
Impact of atogepant on migraine day reduction, response rate, and patient-reported outcomes in participants with episodic migraine and comorbid depressive symptoms: subgroup analysis from the ELEVATE trial
Further involvements
Abstract lecture
AL006
Headwork as innovative tool for monitoring mAbs efficacy in migraine and their influence on work activity: a multicentric experience
ePoster
P045
Effect of atogepant on the migraine disability assessment, work productivity and activity impairment questionnaire, and patient global impression of change: results from the ELEVATE trial
ePoster
P031
Impact of atogepant on migraine day reduction, response rate, and patient-reported outcomes in participants with episodic migraine and comorbid depressive symptoms: subgroup analysis from the ELEVATE trial
ePoster
P013
Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA. The RAMO study: early results
© Conventus Congressmanagement & Marketing GmbH
Imprint
Privacy